Alimera Sciences, Inc.
(NASDAQ : ALIM)

( )
ALIM After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Yes, 3x ETFs are Awesome!
Like TNA, UGAZ, UWTI, NUGT? We do too...Join Up!
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. -1.98%346.610.0%$6595.25m
BNTXBioNTech SE 3.61%340.210.0%$1132.49m
SNSSSunesis Pharmaceuticals, Inc. 2.95%10.830.7%$757.06m
NVAXNovavax, Inc. 1.89%182.7279.8%$661.31m
AMGNAmgen, Inc. -0.73%239.791.3%$495.63m
BIIBBiogen, Inc. 1.52%331.701.7%$437.82m
VRTXVertex Pharmaceuticals, Inc. -1.62%198.321.9%$408.02m
GILDGilead Sciences, Inc. 0.09%68.351.0%$401.65m
REGNRegeneron Pharmaceuticals, Inc. 0.44%577.132.7%$355.44m
ILMNIllumina, Inc. -0.56%492.993.5%$262.54m
NTLAIntellia Therapeutics, Inc. -3.72%136.572.3%$254.07m
CRSPCRISPR Therapeutics AG 1.09%122.340.6%$146.30m
EXASEXACT Sciences Corp. 0.52%108.4018.1%$124.23m
SGENSeagen Inc. 0.55%154.245.8%$120.89m
OCGNOcugen, Inc. 2.09%6.850.0%$113.49m

Company Profile

Alimera Sciences, Inc. engages in the research and development of biopharmaceutical products. It operates through the following geographical segments: U.S. and International. The firm focuses on the development of ophthalmic pharmaceuticals for the treatment of diabetic macular edema, wet and dry age-related macular degeneration and retinal vein occlusion. Its products include ILUVIEN and NADPH Oxidase Inhibitors. The company was founded by Daniel C. Myers and David R. Holland on June 4, 2003 and is headquartered in Alpharetta, GA.